Chimerix rises after upbeat 2022 revenue

Chimerix

02/03/2023 15:48

** Shares of drug developer Chimerix Inc  CMRX.O  rise 5.2%
to $1.67
    ** Co reports 2022 revenue of $33.8 million, marginally
above analysts' average estimate of $33.58 million -Refinitiv 
    ** Co swings to a profit of $172.2 million or $1.94 per
share in FY 2022
    ** CMRX reported a net loss of $173.2 million, or $2.04 per
share in FY 2021  
    ** Says the profit was primarily driven by the sale of co's
smallpox drug, Tembexa, to Emergent BioSolutions  EBS.N  - CMRX
    **  Says it has $266 million in cash as of Dec. 31, 2022 and
no debt 
    ** Including session's moves, stock fell ~72% in the past 12
months

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))